$VSTS

Vestis Corp

Insider trades

No enriched coverage for $VSTS in the last 7 days.

No SEC Form 4 filings for $VSTS in the last 30 days.

See all $VSTS insider activity →
Low

Vestis Corp (VSTS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Vestis Corp (VSTS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. vsts-20260612 0001967649 FALSE 0001967649 2026-06-12 2026-06-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 8-K ___________________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O

Vestis Corporation (NYSE:VSTS) Just Reported And Analysts Have Been Lifting Their Price Targets

Vestis Corporation (NYSE:VSTS) saw its share price jump 31% after reporting second-quarter results broadly in line with analyst revenue estimates, though EPS forecasts for 2026 were subsequently downgraded. Despite the lowered EPS outlook, analysts increased their price targets by 19% to US$9.30, suggesting long-term value. The company's revenue growth is projected to decline, performing worse than the industry average, yet the price target upgrade indicates a belief in improved intrinsic value over time.

Vestis Faces Legal Scrutiny and Stock Struggles Amid Revenue Forecasts

Vestis Corporation's stock has dropped by 12.87% due to leadership reshuffle concerns and legal scrutiny over allegedly misleading financial guidance. The company faces a challenging fiscal year with modest to negative revenue forecasts, cautious EBITDA predictions, and a high debt-to-equity ratio. Despite some efficient cost management indicated by a 27.4% gross margin, investors remain wary, demanding strategic pivots and fortified corporate ethics to regain trust.

VSTS sentiment & insider activity

Recent VSTS coverage spans financial news and corporate actions.

What's driving VSTS

  • The 8-K discloses revised executive compensation and vesting/repayment mechanics for the interim CFO, which can affect near-term governance/overhang perceptions but not operating guidance.

    SEC EDGAR 8-K · Jun 15, 2026

  • Vestis Corporation experienced a significant stock price increase of 31% following its quarterly report, despite some downward revisions in EPS forecasts. Analysts have increased their price targets by 19%, indicating confidence in the company's long-term intrinsic value, even amid projected revenue declines and below-industry performance.

    Simply Wall Street · May 15, 2026

  • Vestis Corporation faces significant headwinds with legal scrutiny, leadership reshuffle, and modest revenue forecasts, leading to a bearish outlook for the stock.

    StocksToTrade · Jan 15, 2026

  • Vestis Corporation is scheduled to release Q4 earnings on December 1, with analysts expecting modest earnings of 6 cents per share on revenue of approximately $678 million. The news indicates a potential for stock movement based on earnings results and analyst revisions.

    Benzinga · Nov 28, 2025

  • The investigation alert concerning Vestis (VSTS) indicates potential legal or regulatory issues that could negatively impact the company's stock price in the short to medium term. The news may lead to increased volatility and a possible decline if the investigation results in adverse outcomes.

    Benzinga · Oct 23, 2025

alphai scores every news story that mentions VSTS with an AI model for sentiment and relevance, and aggregates insider trades from Vestis Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $VSTS

Score
$VSTSLow

Vestis Corp (VSTS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Vestis Corp (VSTS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. vsts-20260612 0001967649 FALSE 0001967649 2026-06-12 2026-06-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 8-K ___________________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O

Vestis Corporation (NYSE:VSTS) Just Reported And Analysts Have Been Lifting Their Price Targets

Vestis Corporation (NYSE:VSTS) saw its share price jump 31% after reporting second-quarter results broadly in line with analyst revenue estimates, though EPS forecasts for 2026 were subsequently downgraded. Despite the lowered EPS outlook, analysts increased their price targets by 19% to US$9.30, suggesting long-term value. The company's revenue growth is projected to decline, performing worse than the industry average, yet the price target upgrade indicates a belief in improved intrinsic value over time.

$VSTSMed

Vestis Faces Legal Scrutiny and Stock Struggles Amid Revenue Forecasts

Vestis Corporation's stock has dropped by 12.87% due to leadership reshuffle concerns and legal scrutiny over allegedly misleading financial guidance. The company faces a challenging fiscal year with modest to negative revenue forecasts, cautious EBITDA predictions, and a high debt-to-equity ratio. Despite some efficient cost management indicated by a 27.4% gross margin, investors remain wary, demanding strategic pivots and fortified corporate ethics to regain trust.

$AMLXMed

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf - Five Below (NASDAQ:FIVE), Amylyx Pharmaceuticals (NASDAQ:AMLX)

PHILADELPHIA, Oct. 09, 2025 ( GLOBE NEWSWIRE ) -- Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) - Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) as securities fraud class action ...

$AMLXLow

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf - Humana (NYSE:HUM), Amylyx Pharmaceuticals (NASDAQ:AMLX)

PHILADELPHIA, Oct. 08, 2025 ( GLOBE NEWSWIRE ) -- Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) as securities fraud class action survives a motion to dismiss.

$HUMLow

Important Notice to Long-Term Shareholders of Humana Inc. (NYSE: HUM); Jasper Therapeutics, Inc. (NASDAQ: JSPR); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf - Humana (NYSE:HUM), Jasper Therapeutics (NASDAQ:JSPR)

PHILADELPHIA, Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- Grabar Law Office is investigating claims on behalf of shareholders of Humana Inc. ( NYSE:HUM ) . The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

$HUMLow

Important Notice to Long-Term Shareholders of Fluor Corporation (NYSE: FLR); Humana Inc. (NYSE: HUM); Maison Solutions Inc. (NASDAQ: MSS); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf - Humana (NYSE:HUM), Fluor (NYSE:FLR)

PHILADELPHIA, Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- Grabar Law Office is investigating claims on behalf of shareholders of Fluor Corporation ( NYSE:FLR ) . The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

Related tickers